Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Abstrakt

Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.